Global HIV, Hepatitis and STIs Programmes
The Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes leads the development and implementation of the global health sector strategy on the elimination of the diseases as public health threats.

People in prisons and other closed settings

HIV, tuberculosis and viral hepatitis – notably hepatitis C virus (HCV) – are of major concern for people detained in prisons and other closed settings. Available data demonstrate that 1 in 4 detainees are HCV-positive, and the estimated global HIV prevalence in prisoners is 3% (UNODC, 2020).

Access to recommended prevention, testing and treatment for these conditions is often not available in prisons. When it is, services are generally inequitable to those available in the community.

WHO, with the United Nations Office on Drugs and Crime (UNODC) and other partners, supports the implementation of comprehensive HIV and HCV services for people who live in prisons and other closed settings.

Worldwide, 30 million people a year will spend time in prison. And across all 5 continents, prison populations are growing. On any given day in 2018, more than 11 million people worldwide, including at least 410 000 children, were held in prisons – a total growth of 24% since 2000. While women prisoners are still a small minority in most countries, their numbers have grown by 50% over the same time period. Member States resort to imprisonment at very different degrees. While the average imprisonment rate at the global level stands below 150 prisoners per 100 000 of the national population, it reaches a rate of 300–650 prisoners per 100 000 of the national population in more than 25 Member States (1).

Female prisoners make up 5–10% of the global prison population. They are more likely to use drugs, and their populations often have higher prevalence rates for HIV (double or more) when compared to male prisoners. Globally, the number of incarcerated women is growing, increasing by an average of 16% in the last 6 years. Women in prison are vulnerable to gender-based sexual violence. They may engage in risky behaviours and practices, such as unsafe tattooing and injecting drug use, and they are more susceptible to self-harm.

People who use drugs are over-represented in many prison populations due to criminalization of drug use and drug possession. Furthermore, some people start using drugs in prison, or start using additional drugs or engaging in riskier injecting practices while incarcerated. Syringe sharing among people who inject drugs is common in prisons. This is exacerbated by a lack of needle/syringe programmes in prison settings worldwide. Other risk factors include unsafe sex due to a lack of availability of condoms in prisons, sexual violence, other high-risk sexual behaviours, and tattooing and piercing.


(1) See United Nations surveys on crime trends and the operations of criminal justice systems (UN-CTS), complemented by data from the World Prison Population and World Female Imprisonment Lists, World Prison Brief (Institute for Crime & Justice Policy Research, Birkbeck, University of London), and the UN Global study on children deprived of liberty (A/74/136).

 Priority health interventions targeting prevention of HIV, viral hepatitis and other STIs among people in prison and other closed settings include:

 

Essential for impact: enabling interventions

Essential for impact: health interventions

Essential for broader health: health interventions

 

  • Removing punitive laws, policies and practices
  • Reducing stigma and discrimination
  • Community empowerment
  • Addressing violence

Prevention of HIV, viral hepatitis and STIs

  • Harm reduction (needle and syringe programmes, OAMT and naloxone for overdose management)
  • Condoms and lubricant
  • PrEP for HIV
  • PEP for HIV and STIs
  • Prevention of vertical transmission of HIV, syphilis and hepatitis B virus (HBV)
  • HBV vaccination

Diagnosis

  • HIV testing services
  • STI testing
  • Hepatitis B and C testing 

Treatment

  • HIV treatment
  • Screening, diagnosis, treatment and prevention of HIV-associated TB
  • STI treatment 
  • HBV and HCV treatment

 

  • Anal health
  • Conception and pregnancy care
  • Contraception
  • Mental health 
  • Prevention, assessment and treatment of cervical cancer
  • Safe abortion
  • Screening and treatment for hazardous and harmful alcohol and other substance use
  • Tuberculosis prevention, screening, diagnosis and treatment

Latest policy guidance

Recommended package of interventions for HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for people in prisons and other closed settings
In this policy brief, we give an update on those parts of the WHO 2022 Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment...
Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations

The Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations outline a public health response...

Policy brief: Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations

The 2022 Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations outline a public health...

Publications

Recommended package of interventions for HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for people in prisons and other closed settings

In 2022, WHO published the Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. These...

New good practice statement on counselling behavioural interventions for key populations to prevent HIV, viral hepatitis and STIs

Key populations (men who have sex with men, people who inject drugs, sex workers, trans and gender diverse people and people in prisons) are at increased...

New recommendation on hepatitis C virus testing and treatment for people at ongoing risk of infection

In 2022, WHO published the Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations....

Why people living and working in detention
facilities should be included in national
COVID-19 vaccination plans

Developed by WHO Health in Prisons Programme (‎HIPP)‎, United Nations Office on Drugs and Crime (‎UNODC)‎ and Penal Reform International...

Access to hepatitis C testing and treatment for people who inject drugs and people in prisons — a global perspective

WHO estimates that 71 million people worldwide were chronically infected with hepatitis C virus (HCV) in 2017. Globally, 23% of new HCV infections and...

Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations

In this consolidated guidelines document on HIV prevention, diagnosis, treatment and care for key populations, WHO brings together all existing guidance...

Tool to set and monitor targets for HIV prevention, diagnosis, treatment and care for key populations

This supplement provides technical guidance to assist countries in planning and monitoring efforts to address HIV among key populations: men who have sex...

Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations

In this new consolidated guidelines document on HIV prevention, diagnosis, treatment and care for key populations, the World Health Organization brings...